As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") moved to establish a multi-district litigation ("MDL") for its aflibercept BPCIA litigation.
On April 12, 2024, the Federal Circuit dismissed CAFC Appeal No. 24-1402 and Cross-Appeal No. 24-1405 for lack of jurisdiction following its February 22, 2024 order directing Regeneron.
There has been a flurry of activity relating to proposed EYLEA® (aflibercept) biosimilars in November, starting with a BPCIA litigation against Celltrion’s proposed biosimilar CT-P42.
Human Insulin Market Size By Type (Traditional Human Insulin and Modern Human Insulin), By Distribution Channel (Hospitals, Retail Pharmacies, And Others),.
2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology.